Champignon Brands Inc News - SHRM

Champignon Provides Update on Disclosure Review

VANCOUVER, British Columbia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (CSE: SHRM) (the...

Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment C...

VANCOUVER, British Columbia, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (CSE: SHRM) (the...

Champignon Announces Filing of Business Acquisition Reports and Appointment of Director

VANCOUVER, British Columbia, July 24, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the...

Champignon Provides Corporate Update

VANCOUVER, British Columbia, July 13, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the...

Champignon Announces Regulatory Review

VANCOUVER, British Columbia, June 22, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the...

REPEAT - Champignon’s Dr. McIntyre / Canadian Rapid Treatment Centre of Excellence (CRTCE) Published in Two Peer Reviewed S...

VANCOUVER, British Columbia, June 19, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the...

Champignon’s Dr. Mcintyre / Canadian Rapid Treatment Centre of Excellence (CRTCE) Published in Two Peer Reviewed Study Jour...

VANCOUVER, British Columbia, June 19, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the...

REPEAT - Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out

VANCOUVER, British Columbia, June 15, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the...

Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out

VANCOUVER, British Columbia, June 12, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the...

Champignon Announces Closing of $15 Million Bought Deal Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER...

REPEAT - Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE...

VANCOUVER, British Columbia, June 08, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496...

Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portf...

VANCOUVER, British Columbia, June 08, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the...

REPEAT - Champignon Appoints Dr. Bill Wilkerson, Executive Chairman of Mental Health International to Board of Directors

VANCOUVER, British Columbia, May 25, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the...

Champignon Appoints Dr. Bill Wilkerson, Executive Chairman of Mental Health International to Board of Directors

VANCOUVER, British Columbia, May 25, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the...

REPEAT - Champignon Sponsors Non-profit Coalition, TheraPsil - Medical Psilocybin Access Project for Palliative Cancer Patien...

VANCOUVER, British Columbia, May 19, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Champignon Brands Inc (SHRM)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

SHRM News

Champignon Provides Update on Disclosure Review

Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment C...

Champignon Announces Filing of Business Acquisition Reports and Appointment of Director

Champignon Provides Corporate Update

Champignon Announces Regulatory Review

REPEAT - Champignon’s Dr. McIntyre / Canadian Rapid Treatment Centre of Excellence (CRTCE) Published in Two Peer Reviewed S...

Champignon’s Dr. Mcintyre / Canadian Rapid Treatment Centre of Excellence (CRTCE) Published in Two Peer Reviewed Study Jour...

REPEAT - Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out

Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out

Champignon Announces Closing of $15 Million Bought Deal Private Placement

REPEAT - Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE...

Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portf...

REPEAT - Champignon Appoints Dr. Bill Wilkerson, Executive Chairman of Mental Health International to Board of Directors

Champignon Appoints Dr. Bill Wilkerson, Executive Chairman of Mental Health International to Board of Directors

REPEAT - Champignon Sponsors Non-profit Coalition, TheraPsil - Medical Psilocybin Access Project for Palliative Cancer Patien...

SHRM Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Champignon Brands Inc (SHRM) News

Champignon Brands Inc (SHRM)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

SHRM News

Champignon Provides Update on Disclosure Review

Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment C...

Champignon Announces Filing of Business Acquisition Reports and Appointment of Director

Champignon Provides Corporate Update

Champignon Announces Regulatory Review

REPEAT - Champignon’s Dr. McIntyre / Canadian Rapid Treatment Centre of Excellence (CRTCE) Published in Two Peer Reviewed S...

Champignon’s Dr. Mcintyre / Canadian Rapid Treatment Centre of Excellence (CRTCE) Published in Two Peer Reviewed Study Jour...

REPEAT - Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out

Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out

Champignon Announces Closing of $15 Million Bought Deal Private Placement

REPEAT - Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE...

Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portf...

REPEAT - Champignon Appoints Dr. Bill Wilkerson, Executive Chairman of Mental Health International to Board of Directors

Champignon Appoints Dr. Bill Wilkerson, Executive Chairman of Mental Health International to Board of Directors

REPEAT - Champignon Sponsors Non-profit Coalition, TheraPsil - Medical Psilocybin Access Project for Palliative Cancer Patien...

SHRM Discussion

Your Recent History